The current standards of mental healthcare are simply not enough - Learn why Palo Santo is funding the change.
Prevalence Of Mental Health Conditions Worldwide
The direct and indirect cost of mental health conditions globally was estimated at $2.5 trillion in 2010 and is projected to surge to $6.0 trillion by 2030. Covid has only exacerbated an existing mental health crisis, with reported anxiety and depression rates tripling from their pre-Covid levels.
Current Standards of Treatment are Inadequate
The demands for mental health treatment are large and growing, the current standard of care has proven inadequate, and there has been minimal innovation over the past 30 years. The Covid-19 pandemic has exacerbated this crisis.
Breakthrough Solutions
Rigorous clinical trials demonstrate the ability of psychedelic medicines to treat mental health disorders more rapidly and durably than currently available treatments. An evolving research and regulatory landscape, along with rapidly shifting cultural attitudes, have expedited the adoption of psychedelics as therapeutics.
Funding the Change
Palo Santo is investing across a diverse ecosystem of psychedelic-focused businesses. Our team brings decades of experience in investing and portfolio building in PE & VC, along with experience in life sciences and healthcare services. Additionally, we are accompanied by the leading academics and advisors in psychedelic science.
WHERE WE INVEST
We invest in businesses focused on all therapeutic applications of psychedelics, as well as other novel treatments for CNS disorders
- Drug Discovery & Development
- API Formulation, Synthesis & Manufacturing Processes
- Tech Enabled Healthcare Solutions, Digital Therapeutics, & Experiential Healing
- Site-Based Healthcare & Consumer-Facing Applications